paediatric cancer
Recently Published Documents


TOTAL DOCUMENTS

252
(FIVE YEARS 74)

H-INDEX

26
(FIVE YEARS 3)

2022 ◽  
Vol 19 ◽  
pp. 100347
Author(s):  
Hong Xiao ◽  
Fang Liu ◽  
Yao He ◽  
Xiaochen Dai ◽  
Zhenhui Liu ◽  
...  

Author(s):  
N.S. Artomova ◽  
N.I. Hasiuk ◽  
O.O. Kaliuzhka ◽  
M.M. Fastovets ◽  
G.O. Soloviova

Communication during the treatment process is vital as it relates directly to the treatment outcomes. For patients and their family members, obtaining and possessing reliable information is essential for building successful and strong communication between physician, patient and in cases of paediatric cancer, the official guardians of the child and family members. The purpose of the study is to identify and analyse communication barriers in communication between physicians and parents (guardians), medical staff and parents (guardians) of paediatric cancer patients. Materials and methods. A retrospective cohort research among parents of paediatric cancer patients who took care of their children while receiving programmed chemotherapy was carried out. The information was collected indirectly: the information was provided by respondents remotely and anonymously using Google Forms. Results. The survey involved 106 family members of paediatric cancer patients receiving treatment at Ukrainian medical institutions specializing in the paediatric cancer treatment. 66% (n=70) of the respondents indicated that it was difficult to find contact with physicians; 85% (n=90) of respondents stated that it was difficult to find the contact with nurses and medical staff; 39,2% of the respondents reported the communication lapses with their attending physicians because the latter were busy and had no enough time to communicate. Considering that the overwhelming majority of respondents (79, 3%) noted physicians and medical staff as the most convenient source of reliable information on paediatric cancer, the researchers proposed to create an information platform for parents of paediatric cancer patients in order to provide access to information on the main issues of paediatric cancer. Conclusions. The research has revealed the following challenges: lack of adequate communication between the patients’ parents and physicians and / or medical staff; parents’ feeling unprepared to receive and comprehend information because of emotional trauma; poor communication between parents and physicians and / or medical staff due to the lack of time. A tool to eliminate these communication barriers can be suggested: this implies the creation of a video channel with visual thematic and clearly structured content for parents of paediatric cancer patients.


PLoS ONE ◽  
2021 ◽  
Vol 16 (10) ◽  
pp. e0258514
Author(s):  
Cho Lee Wong ◽  
Chi Kong Li ◽  
Kai Chow Choi ◽  
Winnie Kwok Wei So ◽  
Jojo Yan Yan Kwok ◽  
...  

Background Anxiety, nausea and vomiting are common side effects suffered by paediatric patients receiving chemotherapy. Emerging evidence supports the efficacy of immersive virtual reality (IVR) on improving anxiety and distress symptoms including nausea and vomiting among this vulnerable group. This trial aims to assess the feasibility and acceptability of IVR for preventing and managing anxiety, nausea and vomiting among paediatric cancer patients receiving their first chemotherapy. Method and analysis An exploratory trial supplemented by qualitative methods will be conducted. We will recruit 20 paediatric patients who are aged between 6 and 12 years, chemotherapy naïve, scheduled to receive their first intravenous chemotherapy and able to understand Chinese. Participants will be randomly allocated to intervention or control groups. The intervention group will receive the IVR intervention for three sessions as follows: 4 hours before chemotherapy, 5 minutes before and during their first course chemotherapy and 5 minutes before and during their second course chemotherapy. The control group will receive standard care only. Main outcome measures included (1) key parameters for the design of a definitive trial (i.e. screening, eligibility, consent and withdrawal rates); (2) anxiety, anticipatory and acute chemotherapy-induced nausea and vomiting for collection of preliminary data; (3) feasibility and acceptability of the intervention. Semi-structured interviews will be conducted with patients, parents and oncology nurses. Generalized estimating equations model will be used to compare each of the outcome measures across the time points between the two groups. Qualitative data will be analysed by conventional content analysis. Expected results The results of this exploratory trial will inform the design and conduct of future definitive trial. Trial registration number ChiCTR1900021694; Pre-results.


2021 ◽  
Vol 23 (Supplement_4) ◽  
pp. iv23-iv23
Author(s):  
Soham Bandyopadhyay ◽  

Abstract Aims Paediatric cancer is a leading cause of non-communicable disease deaths for children worldwide, with more than 90% of deaths occurring in low-and-middle-income countries (LMICs). The COVID-19 pandemic may have exacerbated disparities in paediatric cancer outcomes between LMICs and HICs. The World Health Organization (WHO) Global Initiative for Childhood Cancer has identified gliomas as a common cancer that can act as a benchmark for assessing global paediatric cancer care. This study aims to ascertain the short and medium-term outcome across 17 countries during the COVID-19 pandemic by determining 30- and 90-day all-cause mortality rates for paediatric glioma patients who underwent treatment. Method A multicentre, international, mixed- (retrospective and prospective), collaborative cohort study in 17 countries. Patients were recruited between March 12th 2020 and July 12th 2020. Results 129 patients were recruited with the majority being histologically diagnosed as low-grade gliomas (n = 86/118, 72.9%). Seven children had a change to their planned chemotherapy treatment because of the COVID-19 pandemic. Similarly, seven children and eleven children had a change to their planned radiotherapy treatment and surgical treatment respectively because of the COVID-19 pandemic. Five patients died within the 30-day follow-up period, with all five patients being in LMICs. A sixth child, also in a LMIC, died within the 90-day follow-up period. This significant difference in mortality between LMICs and HICs was present when controlling for confounding for factors such as grade, ASA status, sex, weight, and age. Conclusion There has been relatively minimal change to the treatment of paediatric gliomas worldwide compared to their initial planned care. There was a significant difference in mortality for childhood gliomas between LMICS and high-income countries during the COVID-19 pandemic. There needs to be a concerted effort to improve equity in health outcomes globally.


2021 ◽  
pp. 174239532110431
Author(s):  
Jessica Iyamu ◽  
Jessica C Hodgson ◽  
Rachael Sharpe

Objectives The late effects of paediatric cancer treatment within an educational context are an area that is relatively under researched within the United Kingdom. Methods To support this narrative review, systematic searches were conducted in key scientific databases between May and December 2020. Results Upon reviewing literature within this field, there are key considerations that should be addressed to provide clear and concise findings. These key considerations include clarification on whether the research undertaken focuses on the late or long term effects of paediatric cancer treatment, taking a consistent approach to data analysis with the aim to improve the validity of the study findings, utilising a mixed methodology to gain further depth to the findings as well as increasing the number of studies that focus on a specific tumour type rather than numerous types to allow a detailed study to be undertaken into the potential late effects a treatment for a specific tumour may elicit. Discussion If these key considerations are taken into account when conducting further research within this field, it would enable consistent findings to be utilised in providing the optimum educational provision for survivors of paediatric cancer who remain within the education system.


Author(s):  
Tove Godskesen ◽  
Sara Frygner Holm ◽  
Anna T. Höglund ◽  
Stefan Eriksson

Sign in / Sign up

Export Citation Format

Share Document